The authors defend their choice of standard chemotherapy regimens in the KEYNOTE-024 trial, noting that adding bevacizumab or nab-paclitaxel would likely not have affected outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Dimitri P. Mikhailidis (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: